• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Adverse drugs reactions associated with glaucoma medications.

作者信息

Reyes E, Izquierdo N J, Blasini M

机构信息

Department of Ophthalmology, University of Puerto Rico, San Juan.

出版信息

Bol Asoc Med P R. 1997 Apr-Jun;89(4-6):51-5.

PMID:9284599
Abstract

We undertook a non-concurrent prospective study of 191 Puerto Rican patients from August 1993 to April 1994. All patients had open angle glaucoma (OAG) (age ranged from 50 to 80 yrs; mean = 65 yrs). Patient's symptomatology associated to side effects of their glaucoma medicadons was reviewed. Incidence percent of ocular and/or systemic side effects per medication were: levobunolol 45.0%; betaxolol 42.0%; timolol 27.3%; pilocarpine 100%; dipivefrin 14.0%; and acetazolamide 250 mg 64.1%. Incidence percent of ocular and/or systemic side effects of topical beta-blockers used with concomittant medications were determined. Ocular side effects were more frequent in patients using levobunolol 44.2% than in those patients using betaxolol 42.0%, 8.5% of patients using levobunolol did report systemic side effects. No systemic side effects were reported by patients using betaxolol. Ocular side effects in patients using pilocarpine were frequent (100%); whereas the frequency of systemic side effects was low (6.1%). Systemic side effects were common in patients using carbonic anhydrase inhibitors. These results suggest that non-selective and cardio-selective topical Beta-blockers, differ in their ocular or systemic side effects.

摘要

相似文献

1
Adverse drugs reactions associated with glaucoma medications.
Bol Asoc Med P R. 1997 Apr-Jun;89(4-6):51-5.
2
Comparison of ophthalmic beta-blocking agents.眼科β受体阻滞剂的比较。
Clin Pharm. 1987 Jun;6(6):451-63.
3
Contact dermatitis to topical drugs for glaucoma.青光眼局部用药引起的接触性皮炎。
Am J Contact Dermat. 2001 Dec;12(4):217-9. doi: 10.1053/ajcd.2001.25129.
4
The safety of topical beta-blockers in glaucoma treatment.局部用β受体阻滞剂在青光眼治疗中的安全性。
Med J Aust. 1996 Apr 15;164(8):498-9.
5
Dendritic keratopathy associated with beta-blocker eyedrops.与β受体阻滞剂眼药水相关的树枝状角膜病变
Cornea. 1990 Oct;9(4):335-7.
6
[Beta-blockers in the treatment of open-angle glaucoma].[β受体阻滞剂在开角型青光眼治疗中的应用]
Cesk Slov Oftalmol. 1996 Nov;52(6):399-402.
7
Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.从全身用碳酸酐酶抑制剂转为局部用多佐胺:对有药物相关副作用的青光眼患者生活质量的影响。
Isr Med Assoc J. 2003 Apr;5(4):260-3.
8
The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group.多佐胺/噻吗洛尔联合用药与噻吗洛尔加毛果芸香碱:患者偏好及对日常生活的影响。美国患者偏好研究组。国际患者偏好研究组。
J Glaucoma. 1999 Oct;8(5):315-24.
9
Spirometry for patients prescribed topical beta-blockers.为使用局部β受体阻滞剂的患者进行肺功能测定。
Nurs Stand. 2000;15(4):35-8. doi: 10.7748/ns2000.10.15.4.35.c2929.
10
Physicians' guide to interactions between glaucoma and systemic medications.
J Glaucoma. 1997 Dec;6(6):377-83.

引用本文的文献

1
Graft failure: III. Glaucoma escalation after penetrating keratoplasty.移植失败:III. 穿透性角膜移植术后青光眼病情进展
Int Ophthalmol. 2008 Jun;28(3):191-207. doi: 10.1007/s10792-008-9223-5.
2
Vision related quality of life and topical glaucoma treatment side effects.与视力相关的生活质量及局部青光眼治疗的副作用
Health Qual Life Outcomes. 2003 Dec 10;1:75. doi: 10.1186/1477-7525-1-75.
3
Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries.
多佐胺与布林佐胺治疗高眼压症和原发性开角型青光眼的成本最小化研究:在四个欧洲国家开展。
Pharmacoeconomics. 2003;21(3):201-13. doi: 10.2165/00019053-200321030-00005.